Gilead claims Tru­va­da patents in HHS’ com­plaint are in­valid

25 minutes ago
Pharma

Gilead dusts off a failed Ebo­la drug as coro­n­avirus spreads; Ex­elix­is boasts pos­i­tive Ph I/II da­ta

6 hours ago
Protocols

Deer­field vaults to the top of cell and gene ther­a­py CD­MO game with $1.1B fa­cil­i­ty at Philadel­phi­a's newest bio­phar­ma hub

6 hours ago
Cell/Gene Tx
Outsourcing

Tri­fec­ta of sick­le cell dis­ease ther­a­pies ex­tend life ex­pectan­cy, but are not cost-ef­fec­tive — ICER

6 hours ago
Pharma

A $1B-plus drug stum­bles in­to an­oth­er big PhI­II set­back -- this time flunk­ing fu­til­i­ty test -- as FDA hold re­mains in ef­fect for Ipsen

8 hours ago
R&D

Drug-drug in­ter­ac­tions: FDA is­sues guid­ance on clin­i­cal, in vit­ro stud­ies

8 hours ago
Pharma
Regulatory

Ku­ra co-founder heads to Asian mul­ti-na­tion­al as biotech eyes the goal posts for lead drug

9 hours ago
People

FDA waves Epizyme's $186K rare can­cer drug through to mar­ket — now get ready for the sec­ond act

9 hours ago
Pharma
Regulatory

Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

10 hours ago
R&D

2019 a 'trans­for­ma­tive year' for phar­ma M&A. Is that a good thing?

10 hours ago
Deals
Pharma

Di­a­betes-fo­cused Pox­el names Eli Lil­ly vet David Moller as CSO; Ac­celeron's CBO hops ship to lead start­up

14 hours ago
Peer Review

British Heart Foun­da­tion un­veils short­list for £30M re­search award; On­cono­va scraps Chi­na part­ner­ship

Yesterday
Protocols

Mer­ck KGaA spin­out gets first fund­ing to bring dual-act­ing can­cer mol­e­cules in­to the clin­ic

Yesterday
Startups
Venture

UP­DAT­ED: Eli Lil­ly’s $1.6B can­cer drug failed to spark even the slight­est pos­i­tive gain for pa­tients in its 1st PhI­II

Yesterday
R&D

Am­gen aug­ments Asia foothold by tak­ing over Astel­las joint ven­ture in Japan

Yesterday
China
Deals

PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

Yesterday
Deals

The FDA has de­val­ued the gold stan­dard on R&D. And that threat­ens every­one in drug de­vel­op­ment

Yesterday
Bioregnum
Regulatory

Roche cracks Chi­na's ADC mar­ket open as Kad­cy­la scores its first breast can­cer OK in the coun­try

Yesterday
China
Pharma

UP­DAT­ED: Pas­cal So­ri­ot and As­traZeneca com­mit to ze­ro-car­bon by 2025, car­bon-neu­tral by 2030. Where's the rest of Phar­ma?

Yesterday
R&D

UP­DAT­ED: New play­ers are jump­ing in­to the scram­ble to de­vel­op a vac­cine as pan­dem­ic pan­ic spreads fast

Yesterday
R&D

Fresh tri­al da­ta for­ti­fy po­si­tion of Roche's oral ther­a­py in spinal mus­cu­lar at­ro­phy bat­tle­ground

Yesterday
R&D

Wuhan virus out­break trig­gers in­evitable small-biotech ral­ly

2 days ago
Pharma

Brex­it fears, Wood­ford woes over­shad­owed UK biotech and cut 2019 fi­nanc­ing by al­most half

2 days ago
IPOs
Venture

Blue­print Med­i­cines po­ten­tial­ly de­lays Ay­vak­it de­ci­sion; Con­trol beats treat­ment in mesothe­lioma tri­al

2 days ago
Protocols
1234 Next page Last page